Surgical Science Sweden AB (SUS) — Cash Flow-to-Debt Ratio
Surgical Science Sweden AB (SUS) has a Cash Flow-to-Debt Ratio of 0.17x as of March 2026, meaning its operating cash flow of Skr65.31 Million could theoretically repay 0% of its total liabilities (Skr388.73 Million) in one year. See how financially flexible is Surgical Science Sweden AB to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Surgical Science Sweden AB Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Surgical Science Sweden AB across 11 annual periods. For the full cash flow conversion analysis, see SUS cash flow conversion.
Annual Cash Flow-to-Debt Ratio for Surgical Science Sweden AB (2015–2025)
Year-by-year debt coverage analysis for Surgical Science Sweden AB. Check Surgical Science Sweden AB (SUS) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (SEK) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.19x | Skr79.80 Million | Skr418.31 Million | ▼ -9.5% |
| 2024 | 0.21x | Skr137.22 Million | Skr651.03 Million | ▼ -68.4% |
| 2023 | 0.67x | Skr238.29 Million | Skr357.46 Million | ▲ +112.7% |
| 2022 | 0.31x | Skr129.49 Million | Skr413.11 Million | ▲ +215.2% |
| 2021 | 0.10x | Skr39.08 Million | Skr393.06 Million | ▼ -80.6% |
| 2020 | 0.51x | Skr23.23 Million | Skr45.22 Million | ▼ -49.3% |
| 2019 | 1.01x | Skr55.20 Million | Skr54.54 Million | ▲ +198.4% |
| 2018 | 0.34x | Skr6.88 Million | Skr20.28 Million | ▼ -42.7% |
| 2017 | 0.59x | Skr7.94 Million | Skr13.40 Million | ▲ +82.6% |
| 2016 | 0.32x | Skr13.40 Million | Skr41.30 Million | ▲ +51.8% |
| 2015 | 0.21x | Skr7.50 Million | Skr35.10 Million | — |